US Diverticular Disease Market

ID: MRFR/Pharma/15195-HCR 100 Pages Satyendra Maurya Last Updated: September 15, 2026
US Diverticular Disease Market Research Report By Type (Diverticulosis, Diverticulitis), By Treatment (Medication, Supportive Care, Surgery), By Diagnosis (CT Scan, Ultrasound, Urine Test, Blood Test) and By End User (Hospitals, Specialty Centers) - Growth & Industry Forecast 2025 To 2035
US Diverticular Disease Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.37%
2024 Market Size$ 348.65 Million
2025 Market Size$ 377.84 Million
2035 Market Size$ 844.07 Million
Key Players
AbbVie Inc
Bristol-Myers Squibb Company
Johnson & Johnson
Merck & Co.
Inc.
Pfizer Inc.
Opportunities
  • Rising Healthcare Expenditure
  • Advancements in Treatment Modalities
  • Increased Focus on Dietary Management
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Type (USD Million)
      1. 4.1.1 Diverticulosis
      2. 4.1.2 Diverticular bleeding
      3. 4.1.3 Diverticulitis
    2. 4.2 Chemicals and Materials, BY Treatment (USD Million)
      1. 4.2.1 Medications
      2. 4.2.2 Surgery
      3. 4.2.3 Supportive care
      4. 4.2.4 Penicillin Antibiotic
      5. 4.2.5 Antibiotics
      6. 4.2.6 Dietary Supplements
      7. 4.2.7 IV fluids
    3. 4.3 Chemicals and Materials, BY Diagnosis (USD Million)
      1. 4.3.1 Barium X-ray
      2. 4.3.2 CT scan
      3. 4.3.3 Liver function test
      4. 4.3.4 Blood test
      5. 4.3.5 Urine test
      6. 4.3.6 Ultrasound
    4. 4.4 Chemicals and Materials, BY End User (USD Million)
      1. 4.4.1 Specialty centers
      2. 4.4.2 Hospitals
      3. 4.4.3 Research centers
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AbbVie Inc (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb Company (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Johnson & Johnson (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Merck & Co., Inc. (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer Inc. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen Inc. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Gilead Sciences, Inc. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Takeda Pharmaceutical Company Limited (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY TREATMENT
    4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    12. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 TO 2035 (USD Million)
    16. 6.16 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    18. 6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
      3. 7.2.3 BY DIAGNOSIS, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Diverticular Disease Market Segmentation

US Diverticular Disease Market By Type (USD Million, 2025-2035)

  • Diverticulosis
  • Diverticular bleeding
  • Diverticulitis

US Diverticular Disease Market By Treatment (USD Million, 2025-2035)

  • Medications
  • Surgery
  • Supportive care
  • Penicillin Antibiotic
  • Antibiotics
  • Dietary Supplements
  • IV fluids

US Diverticular Disease Market By Diagnosis (USD Million, 2025-2035)

  • Barium X-ray
  • CT scan
  • Liver function test
  • Blood test
  • Urine test
  • Ultrasound

US Diverticular Disease Market By End User (USD Million, 2025-2035)

  • Specialty centers
  • Hospitals
  • Research centers
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.